IDENTIFICATION OF PATIENTS NOT REQUIRING ENDOMYOCARDIAL BIOPSIES LATE AFTER CARDIAC TRANSPLANTATION
- 1 February 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 65 (4) , 533-538
- https://doi.org/10.1097/00007890-199802270-00014
Abstract
The risk for rejection is highest early, but graft rejection requiring intensified immunosuppression may be present even late after transplantation. Nonetheless, a considerable number of patients are absolutely free of rejection requiring intensified immunosuppression (Rej) late after transplantation. Therefore, we tried to identify patients who do not need endomyocardial biopsies > or = 2 years after transplantation and those who may benefit from long-term follow-up with routine endomyocardial biopsies. A total of 112 patients (age 45+/-12 years) had a follow-up with regular endomyocardial biopsies of > or = 3 years. A total of 4194 endomyocardial biopsies were performed (1364 > or = 2 years after transplantation). They were divided into three categories: rejection score=0, Texas 0-2 or International Society for Heart and Lung Transplantation (ISHLT) 0 or 1A; rejection score=1, Texas 3-4 or ISHLT 1B or 2; rejection score=2, Texas > or = 5 or ISHLT > or = 3A. During the third and subsequent posttransplantation years, 31 of 112 (28%) patients had < or = 1 further Rej (total 51). Independent predictors identifying patients with Rej in multivariate analysis were age [odds ratio (OR)=0.96 per year, P25 years, sum of rejection score < or = 17, and mean cyclosporine level <90th percentile during the first 2 years would not have needed biopsies in the third and subsequent years, whereas the other 48% had a risk of 54% to develop further Rej. In addition to predictors identifying patients with rejection, time after transplantation (OR=0.73 per year, P<0.005), cyclosporine level below therapeutic range (OR=2.15, P<0.05), and reduction of prednisone (OR=2.64, P<0.05) were independent predictors at each endomyocardial biopsy. Risk of Rej remained considerably high in approximately one third of our patients late after transplantation. In these, further surveillance biopsies appear justified, whereas half of the patients had no risk of Rej as long as immunosuppressive therapy was sufficient.Keywords
This publication has 11 references indexed in Scilit:
- Natural Course of Moderate Cardiac Allograft Rejection (International Society for Heart Transplantation Grade 2) Early and Late After TransplantationCirculation, 1996
- Tricuspid valve regurgitation attributable to endomyocardial biopsies and rejection in heart transplantationThe Annals of Thoracic Surgery, 1995
- Cardiac allograft vasculopathy: Current conceptsAmerican Heart Journal, 1995
- Strategies for routine biopsies in heart transplantation based on 8-year results with more than 13,000 biopsiesEuropean Journal of Cardio-Thoracic Surgery, 1995
- Low-dose cyclosporine therapy in triple-drug immunosuppression for heart transplant recipientsThe Annals of Thoracic Surgery, 1994
- Acute rejection after heart transplantation: Noninvasive echocardiographic evaluationJournal of the American College of Cardiology, 1994
- Clinical outcomes after the arterial switch operation for transposition. Patient, support, procedural, and institutional risk factors. Congenital Heart Surgeons Society.Circulation, 1992
- HISTOCOMPATIBILITY AND OTHER RISK FACTORS FOR HISTOLOGICAL REJECTION OF HUMAN CARDIAC ALLOGRAFTS DURING THE FIRST THREE MONTHS FOLLOWING TRANSPLANTATIONTransplantation, 1991
- RISK FACTOR ANALYSIS FOR THE MAJOR HAZARDS FOLLOWING HEART TRANSPLANTATION—REJECTION, INFECTION, AND CORONARY OCCLUSIVE DISEASETransplantation, 1991
- The N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure.Circulation, 1989